Citations

Mayo Clinic

Clear

1099 citation(s) found for "Au, Lewis".

P1‐195: LRRK2 modulation of neuropathology in a mouse model of tauopathy
Bailey, Rachel M. , Melrose, Heather L. , Lewis, Jada , Cannon, Ashley , Farrer, Matthew J. , Dickson, Dennis W.

Alzheimer's & Dementia | July 19, 2012 | Volume: 8 | Issue: 4S_Part_5 | Pages: No page available

10.1016/j.jalz.2012.05.473 Get It

S5‐02‐02: Lessons learned from emerging mouse models of TDP‐43 proteinopathy
Lewis, Jada , D’Alton, Simon , Petrucelli, Leonard , Cannon, Ashley , Dickson, Dennis W.

Alzheimer's & Dementia | July 19, 2012 | Volume: 8 | Issue: 4S_Part_20 | Pages: No page available

10.1016/j.jalz.2012.05.1949 Get It

O4‐07‐06: Influence on phenotype of the postnatal developmental period in mice expressing human M337V TDP‐43
D’Alton, Simon , Altshuler, Marcelle , Petrucelli, Leonard , Lewis, Jada , Cannon, Ashley , Dickson, Dennis W.

Alzheimer's & Dementia | July 19, 2012 | Volume: 8 | Issue: 4S_Part_17 | Pages: No page available

10.1016/j.jalz.2012.05.1676 Get It

Abstract 5363: Dual targeting of mTORC1/C2 complexes enhances histone deacetylase inhibitor-mediated antitumor efficacy in primary HCC cancer in vitro and in vivo
Shao, Huanjie , Tang, Haikuo, Zhang, Hao , Dy, Grace K. , Yu, Chunrong, Adjei, Alex A. , Roberts, Lewis R. , Gao, Chun , Roberts, Lewis R

Cancer Research | June 27, 2012 | Volume: 71 | Issue: 8_Supplement | Pages: 5363-5363

10.1158/1538-7445.am2011-5363 Get It

Abstract The mammalian target of rapamycin (mTOR) consists of two distinct complexes, mTORC1 and mTORC2. mTOR plays a pivotal role in Hepatocellular Carcinoma (HCC). Previous studies indicated that inhibition of mTORC1 only moderately enhanced histone deacetylase inhibitors (HDACis)-mediated anti-tumor activity. This limited effect may be attributable to the increase of AKT activation through S6K1-IRS1-PI3K negative feedback loop triggered by selective mTORC1 inhibition. While as AKT is the downstream effector of mTORC2, we hypothesize that dual targeting of mTORC1/C2 would be more efficient in suppressing AKT and in enhancing anti-tumor activity of HDACi. In this study, the interactions between mTOR kinase inhibitors (mTORKis) and HDACis were examined in vitro using established HCC cell lines and in vivo using patient-derived HCC tumor xenografts on SCID mice. Our results demonstrate that inhibition of both mTORC1/2 not only effectively blocked mTORC1 signaling, but also abrogated negative-feedback activation of AKT caused by mTORC1 inhibition. Furthermore, inactivation of mTORC1/C2 by mTORKis substantially enhanced HDACi-induced anti-tumor activity. Either dysfunction of mTORC2 by knockdown of Rictor (a component of mTORC2), or diminution of AKT1 significantly lowered the threshold of HDACi-induced apoptosis. Lastly, in vivo study indicated that the combination of AZD8055 and Vorinostat yielded much greater tumor-growth inhibition compared to either agent alone in primary HCC xenografts without obvious adverse effects. Conclusion: Dual mTORC1/2 inhibition is more efficient than selective mTORC1 inhibition in enhancing anti-tumor activity of HDACi due to abrogation of negative-feedback activation of AKT induced by selective mTORC1 inhibition. Our findings suggest that combining regimen of mTORKi and HDACi may be an effective therapeutic strategy for HCC. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 5363. doi:10.1158/1538-7445.AM2011-5363
Abstract 1183: miR-199a-3p targets CD44 and reduces proliferation of CD44 positive hepatocellular carcinoma cell lines
Henry, Jon C., Jiang, Jinmai , Kim, Ji Hye , Roberts, Lewis R. , Nagorney, David M. , Banerjee, Soma , Schmittgen, Thomas D. , Park, Jong Kook , Roberts, Lewis R

Cancer Research | June 27, 2012 | Volume: 71 | Issue: 8_Supplement | Pages: 1183-1183

10.1158/1538-7445.am2011-1183 Get It

Abstract Previous work by us and others reported decreased expression of miR-199a-3p in hepatocellular carcinoma (HCC) tissues compared to adjacent benign tissue. We report here a significant reduction of miR-199a-3p expression in 7 HCC cell lines (Huh7, HepG2, SNU182, PLC/PRF/5, Hep3B, SNU423 and SNU449) compared to primary hepatocytes. To determine if miR-199a-3p has a tumor suppressive role, miR-199a-3p mimetic was transfected into the 7 HCC cell lines. miR-199a-3p mimetic reduced cell proliferation by approximately 60% compared to control oligonucleotide in only two cell lines (SNU449 and SNU423); the proliferation of the other 5 treated cell lines was similar to control oligonucleotide. A miR-199a-3p mimetic formulated with chemical modifications to enhance stability while preserving processing reduced cell proliferation in SNU449 and SNU423 to the same extent as the commercially available miR-199a-3p mimetic. Furthermore, only the duplex miR-199a-3p mimetic, and not the guide strand alone, was effective at reducing cell viability. Since a CD44 variant was essential for c-Met signaling (Orian-Rousseau, et al., Genes Dev. 2002) and c-Met is a known miR-199a-3p target, we hypothesized that miR-199a-3p may also target CD44. Indeed, miRNA target algorithms predict miR-199a-3p to be a putative target of CD44. Immunoblotting confirmed that only the HCC lines that were sensitive to the effects of miR-199a-3p mimetic (SNU449 and SNU423) were CD44+. Direct targeting of CD44 by miR-199a-3p was confirmed using luciferase reporter assays and immunoblotting. Transfection of miR-199a-3p into SNU449 cells reduced in vitro invasion and sensitized the cells to doxorubicin; both effects were enhanced when hyaluronic acid was added to the cell cultures. An inverse correlation between the expression of miR-199a-3p and CD44 protein was noted in primary HCC tissue specimens. The anti-proliferative and anti-invasive properties of miR-199a-3p mimetic on CD44+ HCC may be a useful targeted therapy for CD44+ HCC. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 1183. doi:10.1158/1538-7445.AM2011-1183
Neuropilin-1 Stimulates Tumor Growth by Increasing Fibronectin Fibril Assembly in the Tumor Microenvironment
Yaqoob, Usman , Cao, Sheng , Shergill, Uday, Jagavelu, Kumaravelu , Geng, Zhimin , Yin, Meng , Assuncao, Thiago M. de , Cao, Ying , Szabolcs, Anna, Thorgeirsson, Snorri S., Yang, Ju , Roberts, Lewis R. , Shah, Vijay H. , Yaqoob, Usman , Schwartz, Martin A. , Ehman, Richard L. , Mukhopadhyay, Debabrata , Roberts, Lewis R , Yin, Meng

Cancer Research | June 27, 2012 | Volume: 72 | Issue: 16 | Pages: 4047-4059

10.1158/0008-5472.can-11-3907 | PMID 22738912 Get It

Abstract The tumor microenvironment, including stromal myofibroblasts and associated matrix proteins, regulates cancer cell invasion and proliferation. Here, we report that neuropilin-1 (NRP-1) orchestrates communications between myofibroblasts and soluble fibronectin that promote α5β1 integrin–dependent fibronectin fibril assembly, matrix stiffness, and tumor growth. Tumor growth and fibronectin fibril assembly were reduced by genetic depletion or antibody neutralization of NRP-1 from stromal myofibroblasts in vivo. Mechanistically, the increase in fibronectin fibril assembly required glycosylation of serine 612 of the extracellular domain of NRP-1, an intact intracellular NRP-1 SEA domain, and intracellular associations between NRP-1, the scaffold protein GIPC, and the nonreceptor tyrosine kinase c-Abl that augmented α5β1 fibronectin fibril assembly activity. Analysis of human cancer specimens established an association between tumoral NRP-1 levels and clinical outcome. Our findings indicate that NRP-1 activates the tumor microenvironment, thereby promoting tumor growth. These results not only identify new molecular mechanisms of fibronectin fibril assembly but also have important implications for therapeutic targeting of the myofibroblast in the tumor microenvironment. Cancer Res; 72(16); 4047–59. ©2012 AACR.
Abstract B20: GLI1 overexpression contributes to HCC recurrence partly through the induction of SNAI1-induced epithelial-to-mesenchymal transition
Gai, Xiaohong, Fernández-Zapico, Martín E. , Roberts, Lewis R. , Moser, Catherine D., Nakamura, Ikuo , Shire, Abdirashid M., Yang, Judong, Almada, Luciana L. , Thorgeirsson, Snorri S., Zheng, Xin Min , Hu, Chunling , Elsawa, Sherine F. , Roberts, Lewis R

Cancer Research | June 27, 2012 | Volume: 71 | Issue: 18_Supplement | Pages: B20-B20

10.1158/1538-7445.fbcr11-b20 Get It

Abstract Background/Aim: Glioma-associated oncogene 1 (GLI1) is one of the most important transcription factors in the hedgehog (Hh) signaling pathway and has been shown to be involved in embryonic development and tumor progression. The epithelial-to-mesenchymal transition (EMT) is an important cellular program which contributes to invasion and metastasis of cancer. We have previously shown that GLI1 may promote HCC metastasis via EMT. Here, we demonstrate that GLI1 upregulates SNAI1 expression, induces EMT, and promotes HCC recurrence in vivo and in vitro. Methods: Gli1 mRNA was assessed in 139 HCCs by microarray and its correlation with HCC recurrence and SNAI1 mRNA expression was analyzed. In vitro, the mRNA and protein expression of GLI1 was measured in Gli1-negative Huh7 cells transfected with GU1 and GU1-expressing SNU398 cells transfected with antisense oligonucleotides targeting GU1 (GLI1 ASO). GLI1-dependent transcriptional activity was assessed with GU reporter luciferase assay and electrophoretic mobility shift assay (EMSA). The interaction between Gli1, SNAI1 and EMT was assessed by real-time PCR, Western immunoblotting and immunofluorescence. Effects of GLI1 on proliferation, viability, migration, and invasion of tumor cells were also assessed. Results: GLI1 mRNA was detected in 74 HCC tumors and found to be upregulated in 43 (58.1 %) HCCs. Increased Gli1 mRNA in HCCs was associated with tumor recurrence after resection. There was a positive correlation between GLI1 and SNAI1 mRNA expression. In HCC cells, GLI1 overexpression increased Gli1-dependent transcriptional activity, proliferation, viability, migration, and invasion of tumor cells. GU1 also increased SNAI1 expression and induced the EMT. Opposite effects were observed in GU1-knockdown models. Conclusion: Together, these findings identify a novel mechanism mediating HCC recurrence that includes GLI1-mediated activation of EMT via upregulation of SNAI1. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the Second AACR International Conference on Frontiers in Basic Cancer Research; 2011 Sep 14-18; San Francisco, CA. Philadelphia (PA): AACR; Cancer Res 2011;71(18 Suppl):Abstract nr B20.
Dental Abnormalities in Schimke Immuno-osseous Dysplasia
Morimoto, Marie , Kérourédan, Olivia , Gendronneau, M., Shuen, Chao S, Baradaran‐Heravi, Alireza , Asakura, Yumi , Basiratnia, Mitra , Bogdanović, Radovan, Bonneau, Dominique , Buck, A., Charrow, Joel , Cochat, Pierre , DeHaai, Kristi A. , Fenkçi, M Semin, Frange, Pierre, Fründ, Stefan, Fryssira, Helen , Keller, Kory, Kirmani, Salman , Kobelka, Christine, Lewis, David B. , Massella, Laura , McLeod, D. Ross, Milford, David V. , Nobili, François, Olney, Ann Haskins, Semerci, C. Nur, Stajic, Nastasa, Stein, Anja , Taque, Sophie, Zonana, J., Lücke, Thomas , Hendson, Glenda, Bonnaure‐Mallet, Martine , Frange, Pierre , Köhler, Katharina , Boerkoel, Cornelius F.

Journal of Dental Research | June 14, 2012 | Volume: 91 | Issue: 7_suppl | Pages: S29-S37

10.1177/0022034512450299 | PMID 22699664 Get It

Described for the first time in 1971, Schimke immuno-osseous dysplasia (SIOD) is an autosomal-recessive multisystem disorder that is caused by bi-allelic mutations of SMARCAL1, which encodes a DNA annealing helicase. To define better the dental anomalies of SIOD, we reviewed the records from SIOD patients with identified bi-allelic SMARCAL1 mutations, and we found that 66.0% had microdontia, hypodontia, or malformed deciduous and permanent molars. Immunohistochemical analyses showed expression of SMARCAL1 in all developing teeth, raising the possibility that the malformations are cell-autonomous consequences of SMARCAL1 deficiency. We also found that stimulation of cultured skin fibroblasts from SIOD patients with the tooth morphogens WNT3A, BMP4, and TGFβ1 identified altered transcriptional responses, raising the hypothesis that the dental malformations arise in part from altered responses to developmental morphogens. To the best of our knowledge, this is the first systematic study of the dental anomalies associated with SIOD.
Effects of Long-term Infusion of Prostacyclin (Epoprostenol) on Echocardiographic Measures of Right Ventricular Structure and Function in Primary Pulmonary Hypertension
Hinderliter, Alan L. , Willis, Park W., Barst, Robyn J., Rich, Stuart , Rubin, Lewis J. , Badesch, David B., Groves, Bertron Μ., McGoon, Michael D., Tapson, Victor F. , Bourge, Robert C. , Brundage, Bruce H., Koerner, Spencer K., Langleben, David , Keller, Cesar A., Murali, Srinivas, Koch, Gary G., Clayton, Linda, Jöbsis, Maria M., Blackburn, Shelmer D., Crow, James W., Long, Walker, Uretsky, Barry F. , Li, Shu

Circulation | June 12, 2012 | Volume: 95 | Issue: 6 | Pages: 1479-1486

10.1161/01.cir.95.6.1479 | PMID 9118516 Get It

BackgroundRight heart failure is an important cause of morbidity and mortality in primary pulmonary hypertension. In a recent prospective, randomized study of severely symptomatic patients, treatment with prostacyclin (epoprostenol) produced improvements in hemodynamics, quality of life, and survival. This article describes the echocardiographic characteristics of participants in this trial; the relationships of echocardiographic variables to hemodynamic parameters, exercise capacity, and quality of life; and the echocardiographic changes associated with prostacyclin therapy.Methods and ResultsThe 81 patients enrolled in this multicenter trial were randomized to treatment with a long-term infusion of prostacyclin in addition to conventional therapy (n=41) or conventional therapy alone (n=40) for 12 weeks. Echocardiograms and assessments of hemodynamics, exercise capacity, and quality of life were performed before and after the treatment phase. On baseline evaluation, patients had marked right ventricular dilatation and dysfunction, abnormal septal curvature, and significant tricuspid regurgitation with a high regurgitant velocity. Pericardial effusions were common. More pronounced abnormalities in right heart structure and function were associated with higher pulmonary arterial and mean right atrial pressures, lower cardiac index, and impaired exercise capacity but had no predictable relationship to quality-of-life indicators. The 12-week infusion of prostacyclin had beneficial effects on right ventricular size, curvature of the interventricular septum, and maximal tricuspid regurgitant jet velocity.ConclusionsThe echocardiographic manifestations of severe primary pulmonary hypertension reflect abnormalities in hemodynamics and exercise capacity. Prostacyclin has beneficial effects on right heart structure and function that may contribute to the clinical improvement and prolonged survival observed with this drug.
The Lewis A. Conner Memorial Lecture
Edwards, Jesse E.

Circulation | June 11, 2012 | Volume: 15 | Issue: 2 | Pages: 164-196

10.1161/01.cir.15.2.164 | PMID 13396940 Get It

While there are many anatomic varieties of congenital malformations of the heart and great vessels, most may be divided, from a functional point of view, into 3 types: (1) communication between the ventricles or between the aorta and pulmonary arteries, (2) anomalous drainage of pulmonary venous blood into the right atrium, and (3) obstruction to pulmonary venous flow. In each of these categories the responses of the pulmonary vascular tree have to be considered in understanding the altered dynamics. Depending on the type and degree of response in the pulmonary vascular bed, there may be a varying functional picture among patients having the same anatomic or functionally comparable malformation.